TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21723164

Group type: EXPERIMENTAL
Intervention: Sildenafil
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Bosentan
Number of subjects: 16
Study: 21352172

Group type: EXPERIMENTAL
Intervention: Specific Preventive Intervention (SPI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Needs‐Based Intervention (NBI)
Number of subjects: 0
Study: 16490430

Group type: EXPERIMENTAL
Intervention: Rosiglitazone monotherapy at 4 mg/day for 3 months
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Combination therapy with rosiglitazone at 4 mg/day and atorvastatin at 10 mg/day for 3 months
Number of subjects: 30
Study: 12969088

Group type: EXPERIMENTAL
Intervention: L30AC (twice‐daily 30 mg lansoprazole, 1000 mg amoxicillin and 500 mg clarithromycin for 7 days)
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: L15AC (twice‐daily 15 mg lansoprazole, 1000 mg amoxicillin and 500 mg clarithromycin for 7 days)
Number of subjects: 800

Group type: COMPARATOR
Intervention: LP (once‐daily 15 mg lansoprazole for 14 days)
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: H. pylori eradication
Number of subjects: 800
Study: 11038044

Group type: COMPARATOR
Intervention: LV5FU2 regimen (leucovorin 100 mg/m2 + 5-FU 400 mg/m2 bolus + 5-FU 600 mg/m2 infusion)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: LV5FU2 + CPT-11 regimen (CPT-11 at 180 mg/m2 on day 1 before LV5FU2)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: LV5FU2 + CPT-11 regimen
Number of subjects: 102
Study: 9254959

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 1587191

Group type: EXPERIMENTAL
Intervention: Nizatidine 150 mg
Number of subjects: 515

Group type: EXPERIMENTAL
Intervention: Nizatidine 300 mg
Number of subjects: 515

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 515
Study: 3888594

Group type: EXPERIMENTAL
Intervention: Intravenous cimetidine and pirenzepine (group A)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Intragastric magnesium-aluminium-hydroxide concentrate (antacid, group B)
Number of subjects: 125
Study: 31855555

Group type: EXPERIMENTAL
Intervention: Collection of serum at delivery from pregnant women
Number of subjects: 1823

Group type: EXPERIMENTAL
Intervention: Collection of maternal, cord and infant blood samples
Number of subjects: 1823

Group type: EXPERIMENTAL
Intervention: Screening for group B streptococcus
Number of subjects: 1823

Group type: EXPERIMENTAL
Intervention: Collection of blood samples from infants born to colonised women
Number of subjects: 1823

Group type: EXPERIMENTAL
Intervention: Collection of maternal and infant blood and bacterial isolates
Number of subjects: 1823
Study: 27701372

Group type: EXPERIMENTAL
Intervention: Ultrasound (US)-assisted procedure (Group B)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Loss of resistance technique (Group A)
Number of subjects: 58
Study: 27111879

Group type: EXPERIMENTAL
Intervention: Gait retraining (switching from rearfoot strike to forefoot strike)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 16
Study: 24997616

Group type: EXPERIMENTAL
Intervention: Pulsed radiofrequency (PRF)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Steroid + bupivacaine
Number of subjects: 80
Study: 22992072

Group type: EXPERIMENTAL
Intervention: BG-12 (twice-daily, 240 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BG-12 (thrice-daily, 240 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Glatiramer acetate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BG-12 (twice-daily)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BG-12 (thrice-daily)
Number of subjects: 0
Study: 20808333

Group type: EXPERIMENTAL
Intervention: Phytosterol-abundant diet (449 mg phytosterols/2000 kcal)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Phytosterol-poor diet (126 mg phytosterols/2000 kcal)
Number of subjects: 20
Study: 18055931

Group type: EXPERIMENTAL
Intervention: GP education programme and access to LEO CAT
Number of subjects: 150

Group type: COMPARATOR
Intervention: Care as usual
Number of subjects: 150
Study: 16236854

Group type: EXPERIMENTAL
Intervention: COPD patients
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Asymptomatic smokers
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: COPD patients who smoked the same morning
Number of subjects: 40

Group type: COMPARATOR
Intervention: Nonsmokers
Number of subjects: 40
Study: 14601482

Group type: EXPERIMENTAL
Intervention: NIDDM patients
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 34
Study: 9925124

Group type: EXPERIMENTAL
Intervention: Fructooligosaccharides (15 g/d)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Glucose as a placebo (4 g/d)
Number of subjects: 20
Study: 7768081

Group type: EXPERIMENTAL
Intervention: Combined lipo-PGE1/glucagon-insulin therapy (group B)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Glucagon-insulin therapy only (group A)
Number of subjects: 29
Study: 1690483

Group type: EXPERIMENTAL
Intervention: prazosin HCl
Number of subjects: 39

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 39
Study: 6998537

Group type: EXPERIMENTAL
Intervention: Prophylactic co-trimoxazole (single dose)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control group (no prophylactic treatment)
Number of subjects: 68
Study: 31112457

Group type: EXPERIMENTAL
Intervention: 10 session psychiatric standard treatment with added Plan Analysis and Motive Oriented Therapeutic Relationship
Number of subjects: 36

Group type: COMPARATOR
Intervention: 10 session psychiatric standard treatment without the added Plan Analysis and Motive Oriented Therapeutic Relationship
Number of subjects: 36
Study: 28330794

Group type: EXPERIMENTAL
Intervention: Radial access
Number of subjects: 8404

Group type: COMPARATOR
Intervention: Femoral access
Number of subjects: 8404
Study: 25028983

Group type: EXPERIMENTAL
Intervention: Warm water immersion (WI, 30 °C)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Cool water immersion (CI, 26.7 °C)
Number of subjects: 8

Group type: COMPARATOR
Intervention: No immersion (NI)
Number of subjects: 8
Study: 22948339

Group type: EXPERIMENTAL
Intervention: Allergen-specific immunotherapy
Number of subjects: 205

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 205
Study: 21782168

Group type: EXPERIMENTAL
Intervention: Hysteroscopic sterilization with the ESS 305 device by experienced physicians
Number of subjects: 578

Group type: COMPARATOR
Intervention: Hysteroscopic sterilization with the ESS 305 device by novice physicians
Number of subjects: 578

Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 578
Study: 19564449

Group type: EXPERIMENTAL
Intervention: Omalizumab
Number of subjects: 146
Study: 17900321

Group type: EXPERIMENTAL
Intervention: 5 g of a multispecies probiotic, Ecologic AAD (10(9) cfu/g), twice daily for 14 days
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study: 16231754

Group type: EXPERIMENTAL
Intervention: Home blood pressure measurements in treated hypertensive group (n = 70)
Number of subjects: 558

Group type: EXPERIMENTAL
Intervention: Home blood pressure measurements in normotensive group (n = 558)
Number of subjects: 558

Group type: EXPERIMENTAL
Intervention: Home blood pressure measurements in untreated hypertensive group (n = 72)
Number of subjects: 558

Group type: EXPERIMENTAL
Intervention: Comparison of morning home blood pressure in patients taking antihypertensive drugs
Number of subjects: 558
Study: 12228843

Group type: EXPERIMENTAL
Intervention: Candesartan
Number of subjects: 4500

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4500

Group type: COMPARATOR
Intervention: Placebo (mainly hydrochlorothiazide)
Number of subjects: 4500
Study: 10088180

Group type: EXPERIMENTAL
Intervention: Calcitriol p.os 0.5‐1.0 microgram after each dialysis session for 36 months
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control group (no calcitriol treatment)
Number of subjects: 19
Study: 8527710

Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA) 600 mg orally per day for 6 months
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (matched sex, age, and initial serum ALT levels)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA)
Number of subjects: 30
Study: 2334614

Group type: EXPERIMENTAL
Intervention: 10% glucose i.v. during surgery
Number of subjects: 30

Group type: COMPARATOR
Intervention: Ringer‐acetate as the only crystalloid peroperative fluid
Number of subjects: 30
Study: 7190412

Group type: EXPERIMENTAL
Intervention: Clofibate and phenformin
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Clofibate
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Clofibate and biguanide treatment
Number of subjects: 11
Study: 31690536

Group type: EXPERIMENTAL
Intervention: Pulse reproductive health app
Number of subjects: 1304

Group type: COMPARATOR
Intervention: General health app
Number of subjects: 1304
Study: 30115068

Group type: EXPERIMENTAL
Intervention: Plant extract based supplement
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study: 26831610

Group type: EXPERIMENTAL
Intervention: Telmisartan 40/80 mg once daily with lifestyle modification (TL)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Lifestyle modification (L)
Number of subjects: 50
Study: 24284498

Group type: EXPERIMENTAL
Intervention: Low sodium diet (10 mmol/day)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Normal sodium diet (150 mmol)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: High sodium diet (400 mmol)
Number of subjects: 70
Study: 23362618

Group type: EXPERIMENTAL
Intervention: Low-dose MF59-adjuvanted A/H5N1 vaccine (3.75 μg)
Number of subjects: 722

Group type: COMPARATOR
Intervention: Licensed higher-dose A/H5N1 vaccine (7.5 mg)
Number of subjects: 722

Group type: EXPERIMENTAL
Intervention: Both vaccines (low-dose and licensed)
Number of subjects: 722
Study: 19573142

Group type: EXPERIMENTAL
Intervention: Specific Oral Tolerance Induction (SOTI)
Number of subjects: 200
Study: 18581679

Group type: EXPERIMENTAL
Intervention: Interferon plus laser
Number of subjects: 96

Group type: COMPARATOR
Intervention: Interferon
Number of subjects: 96

Group type: COMPARATOR
Intervention: Laser
Number of subjects: 96
Study: 16834647

Group type: EXPERIMENTAL
Intervention: Periprostatic lidocaine injection (5 mL of 2% lidocaine solution injected near the junction of the seminal vesicle with the base of the prostate)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Intrarectal lidocaine gel (20 mL of 2% lidocaine gel intrarectally)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Normal saline injection (5 mL normal saline injected along the neurovascular bundles)
Number of subjects: 90
Study: 14557840

Group type: EXPERIMENTAL
Intervention: Home-made spacer with salbutamol (100 microg/3 kg)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Jet nebulizer with salbutamol (250 microg/3 kg)
Number of subjects: 54
Study: 10574640

Group type: EXPERIMENTAL
Intervention: 2 mg chlormadinone acetate
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 150 microg desogestrel
Number of subjects: 45
Study: 8623152

Group type: EXPERIMENTAL
Intervention: Cyclosporine emulsion capsules
Number of subjects: 101

Group type: COMPARATOR
Intervention: Cyclosporine (oral solution for microemulsion)
Number of subjects: 101
Study: 1778088

Group type: EXPERIMENTAL
Intervention: 50 mg diclofenac dispersible 3-times daily for 4 weeks
Number of subjects: 314

Group type: COMPARATOR
Intervention: Placebo 3-times daily for 4 weeks
Number of subjects: 314

Group type: EXPERIMENTAL
Intervention: 50 mg diclofenac dispersible
Number of subjects: 314

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 314
Study: 6988335

Group type: EXPERIMENTAL
Intervention: Primary suture and plaster‐of‐Paris
Number of subjects: 95

Group type: COMPARATOR
Intervention: Plaster‐of‐Paris only
Number of subjects: 95

Group type: COMPARATOR
Intervention: Strapping
Number of subjects: 95
Study: 30590387

Group type: EXPERIMENTAL
Intervention: Amlodipine (CCB)
Number of subjects: 376

Group type: COMPARATOR
Intervention: Chlorthalidone (thiazide-like diuretic)
Number of subjects: 376

Group type: COMPARATOR
Intervention: Lisinopril (ACE inhibitor)
Number of subjects: 376
Study: 27882611

Group type: EXPERIMENTAL
Intervention: Calcium lactate (CL) supplementation
Number of subjects: 18

Group type: COMPARATOR
Intervention: Sodium bicarbonate (SB) supplementation
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 18
Study: 25832522

Group type: EXPERIMENTAL
Intervention: Heroin-assisted treatment (HAT) for 12 months
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Heroin-assisted treatment (HAT)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Methadone maintenance treatment (Control)
Number of subjects: 74
Study: 23524942

Group type: EXPERIMENTAL
Intervention: Cisplatin (75 mg/m2 on days 1 and 2) and capecitabine (750 mg/m2 in two divided doses from day 1-14)
Number of subjects: 153

Group type: COMPARATOR
Intervention: Cisplatin (75 mg/m2 on days 1 and 2) and 5-FU (750 mg/m2 on days 1, 2, and 3)
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Cisplatin and capecitabine
Number of subjects: 153

Group type: COMPARATOR
Intervention: Cisplatin and 5-FU
Number of subjects: 153
Study: 21596292

Group type: EXPERIMENTAL
Intervention: Cryopexy
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Laser therapy
Number of subjects: 42

Group type: COMPARATOR
Intervention: Observation (Control)
Number of subjects: 42
Study: 19671877

Group type: EXPERIMENTAL
Intervention: ipilimumab with daily blinded budesonide (group A)
Number of subjects: 115

Group type: COMPARATOR
Intervention: ipilimumab with placebo (group B)
Number of subjects: 115
Study: 17334898

Group type: EXPERIMENTAL
Intervention: Modified version of the Rutter parent questionnaire
Number of subjects: 400

Group type: COMPARATOR
Intervention: Standard version of the Rutter parent questionnaire
Number of subjects: 400
Study: 15076126

Group type: EXPERIMENTAL
Intervention: Nurse internship program
Number of subjects: 0
Study: 11322052

Group type: EXPERIMENTAL
Intervention: Frequency Doubling Perimetry (FDP)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Standard Automated Perimetry (HFA)
Number of subjects: 45
Study: 9466064

Group type: EXPERIMENTAL
Intervention: Neomycin/dexamethasone spray (Otomize)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Neomycin/dexamethasone drops
Number of subjects: 0
Study: 8192128

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral relapse prevention treatment
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Twelve-Step recovery support group
Number of subjects: 110

Group type: COMPARATOR
Intervention: Both treatment conditions
Number of subjects: 110

Group type: COMPARATOR
Intervention: Treatment attendance
Number of subjects: 110
Study: 3115445

Group type: EXPERIMENTAL
Intervention: Auscultatory blood pressure measurement with larger cuffs (various lengths and widths)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Auscultatory blood pressure measurement with six cuffs of various lengths and widths
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Auscultatory blood pressure measurement with a single long bladdered cuff
Number of subjects: 37
Study: 30510080

Group type: EXPERIMENTAL
Intervention: Ravulizumab
Number of subjects: 246

Group type: COMPARATOR
Intervention: Eculizumab
Number of subjects: 246
Study: 27849563

Group type: EXPERIMENTAL
Intervention: Intensive treatment
Number of subjects: 897
Study: 25602857

Group type: EXPERIMENTAL
Intervention: Exercise-based cardiac rehabilitation (ECR) consisting of 8 weeks of aerobic exercise at 70-85% of maximal heart rate during 3 sessions weekly plus usual care
Number of subjects: 96

Group type: COMPARATOR
Intervention: Control group (CG) receiving only usual care
Number of subjects: 96
Study: 23777763

Group type: EXPERIMENTAL
Intervention: recombinant von Willebrand factor (rVWF) combined with recombinant factor VIII (rFVIII)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: recombinant von Willebrand factor (rVWF)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: post‐rVWF‐rFVIII infusion
Number of subjects: 32
Study: 20579832

Group type: EXPERIMENTAL
Intervention: Self-confrontation method (SCM), 6 or 12 sessions
Number of subjects: 42

Group type: COMPARATOR
Intervention: Self-confrontation method (SCM), 6 sessions
Number of subjects: 42
Study: 19236972

Group type: EXPERIMENTAL
Intervention: Unilateral posteroanterior (PA) mobilization technique on the painful side
Number of subjects: 60

Group type: COMPARATOR
Intervention: Random mobilization technique
Number of subjects: 60
Study: 16843248

Group type: EXPERIMENTAL
Intervention: Telemedicine evaluation
Number of subjects: 492

Group type: COMPARATOR
Intervention: In-person evaluation
Number of subjects: 492
Study: 15127875

Group type: EXPERIMENTAL
Intervention: BFEO (brushing, flossing and rinsing with an EO-containing mouthrinse)
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: BFC (brushing, flossing and rinsing with a control mouthrinse)
Number of subjects: 246

Group type: COMPARATOR
Intervention: BC (brushing and rinsing with a control mouthrinse)
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: BFEO
Number of subjects: 246
Study: 11726440

Group type: EXPERIMENTAL
Intervention: Immediate extubation (Group 1)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Delayed extubation (Group 2)
Number of subjects: 50
Study: 8996345

Group type: EXPERIMENTAL
Intervention: 200 micrograms desmopressin tablets
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: 400 micrograms desmopressin tablets
Number of subjects: 66

Group type: COMPARATOR
Intervention: 20 micrograms nasal spray
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Desmopressin tablets (both doses)
Number of subjects: 66
Study: 8424470

Group type: EXPERIMENTAL
Intervention: Nortriptyline (100 mg median nightly dose for 6 weeks)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Placebo (for 6 weeks)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Nortriptyline
Number of subjects: 92
Study: 3307548

Group type: EXPERIMENTAL
Intervention: Propanidid (9 mg X kg‐1 IVD, and 60 mg X kg‐1 X h‐1)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Propofol (2.5 mg X kg‐1 IVD, and 9 mg X kg‐1 X h‐1)
Number of subjects: 30
Study: 29466550

Group type: COMPARATOR
Intervention: Traditional treatment (Van Riper, 1939)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Expansion points (Smit, 2000)
Number of subjects: 13
Study: 26871730

Group type: EXPERIMENTAL
Intervention: Real electrical pharyngeal stimulation (EPS)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sham electrical pharyngeal stimulation (EPS)
Number of subjects: 20
Study: 24553365

Group type: EXPERIMENTAL
Intervention: imatinib+interferon (IFN)
Number of subjects: 403

Group type: COMPARATOR
Intervention: imatinib-400mg
Number of subjects: 403

Group type: COMPARATOR
Intervention: imatinib+cytarabine
Number of subjects: 403

Group type: COMPARATOR
Intervention: imatinib-600mg
Number of subjects: 403

Group type: EXPERIMENTAL
Intervention: VEGF low levels at diagnosis
Number of subjects: 403
Study: 22562977

Group type: COMPARATOR
Intervention: adalimumab therapy
Number of subjects: 76
Study: 20581215

Group type: EXPERIMENTAL
Intervention: Pregabalin 75 mg
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Pregabalin 50 mg
Number of subjects: 162

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Pregabalin 50 mg, Pregabalin 75 mg, Placebo
Number of subjects: 162
Study: 17761540

Group type: EXPERIMENTAL
Intervention: Community health worker intervention
Number of subjects: 298
Study: 15935272

Group type: EXPERIMENTAL
Intervention: Metal-free polymer crowns with chamfer finishing line or shoulder preparation
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Patient evaluation of esthetic and functional performance
Number of subjects: 114
Study: 14512676

Group type: EXPERIMENTAL
Intervention: MAGhaler (beclomethasone dipropionate 1,000 microg/day)
Number of subjects: 171

Group type: COMPARATOR
Intervention: MDI (beclomethasone dipropionate 1,000 microg/day)
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: MAGhaler
Number of subjects: 171

Group type: COMPARATOR
Intervention: MDI
Number of subjects: 171
Study: 11826695

Group type: EXPERIMENTAL
Intervention: Injection of 2% xylocaine with 1:80,000 epinephrine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-injected inferior turbinate
Number of subjects: 0
Study: 9893655

Group type: EXPERIMENTAL
Intervention: Primary chemotherapy (FEC: 5‐fluorouracil 600 mg/m2, epidoxorubicin 60 mg/m2, cyclophosphamide 600 mg/m2)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: High [3H]‐dT‐LI
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Low [3H]‐dT‐LI
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Pathological complete response after induction treatment
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Low [3H]‐dT‐LI after primary chemotherapy
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Bcl-2 expression before primary chemotherapy
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Bcl-2 expression after primary chemotherapy
Number of subjects: 70
Study: 7841754

Group type: EXPERIMENTAL
Intervention: Feiyaning (FYN)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Ligustrazine (LT)
Number of subjects: 40
Study: 3277083

Group type: EXPERIMENTAL
Intervention: Clonazepam (0.25 to 0.5 mg/d)
Number of subjects: 12
Study: 30946274

Group type: EXPERIMENTAL
Intervention: Low-Intensity Group (LIG)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Moderate-Intensity Group (MIG)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: High-Intensity Group (HIG)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Comparison of LIG to HIG
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Comparison of LIG and MIG to HIG
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Detraining effects
Number of subjects: 39
Study: 30587469

Group type: EXPERIMENTAL
Intervention: Cough (EMA) granules
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study: 27253184

Group type: EXPERIMENTAL
Intervention: Targeted early intervention program involving home visits from pregnancy onwards
Number of subjects: 164

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 164
Study: 25796512

Group type: EXPERIMENTAL
Intervention: Maternal BMI categories (overweight and obese subclasses)
Number of subjects: 1030

Group type: EXPERIMENTAL
Intervention: GDM diagnosis
Number of subjects: 1030

Group type: EXPERIMENTAL
Intervention: Obesity (independent of GDM)
Number of subjects: 1030